News | November 10, 2022
Lupin Q2 FY2023 revenue remains flat
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Subscribe To Our Newsletter & Stay Updated
